Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1

Interventions

pembrolizumab 2nilotinib 2avapritinib 2trastuzumab deruxtecan 1talquetamab 1pomalidomide 1montelukast 1lazertinib 1larotrectinib 1ivosidenib 1entrectinib 1dostarlimab 1daratumumab 1carfilzomib 1asciminib 1amivantamab 1Thalidomide 1TIC10 compound 1Prednisone 1Pemetrexed 1Melphalan 1Lenalidomide 1Imatinib Mesylate 1Diphenhydramine 1Dexamethasone 1Dasatinib 1Crizotinib 1Carboplatin 1Bortezomib 1Appointments and Schedules 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Has announcements × Appointments and Schedules × Clear all
NCT02631044 2024-06-27

Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)

Juno Therapeutics, a Subsidiary of Celgene

Phase 1 Completed
387 enrolled 2 FDA
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡